Celldex Therapeutics, Inc. $CLDX Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA lessened its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 4.6% during the first quarter, HoldingsChannel reports. The institutional investor owned 923,696 shares of the biopharmaceutical company’s stock after selling 44,920 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Celldex Therapeutics were worth $29,300,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in CLDX. Wellington Management Group LLP lifted its stake in Celldex Therapeutics by 39.3% in the fourth quarter. Wellington Management Group LLP now owns 8,079,608 shares of the biopharmaceutical company’s stock valued at $219,442,000 after buying an additional 2,279,605 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Celldex Therapeutics by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 4,027,407 shares of the biopharmaceutical company’s stock worth $109,384,000 after acquiring an additional 72,817 shares during the last quarter. Bellevue Group AG grew its position in shares of Celldex Therapeutics by 7.6% during the third quarter. Bellevue Group AG now owns 3,557,669 shares of the biopharmaceutical company’s stock worth $92,037,000 after acquiring an additional 250,100 shares during the last quarter. Commodore Capital LP increased its holdings in shares of Celldex Therapeutics by 7.8% in the 2nd quarter. Commodore Capital LP now owns 3,450,000 shares of the biopharmaceutical company’s stock valued at $70,208,000 after acquiring an additional 250,000 shares during the period. Finally, State Street Corp increased its holdings in shares of Celldex Therapeutics by 19.5% in the 4th quarter. State Street Corp now owns 3,397,713 shares of the biopharmaceutical company’s stock valued at $92,282,000 after acquiring an additional 555,579 shares during the period.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Wall Street Zen upgraded shares of Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Monday, April 20th. Wolfe Research upgraded shares of Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 price objective on the stock in a research note on Monday, March 23rd. Wells Fargo & Company increased their target price on shares of Celldex Therapeutics from $38.00 to $54.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th. Finally, UBS Group raised their price target on Celldex Therapeutics from $38.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $49.30.

Celldex Therapeutics Stock Performance

Shares of CLDX opened at $37.21 on Wednesday. The stock has a market capitalization of $2.92 billion, a P/E ratio of -8.73 and a beta of 0.95. The company’s fifty day moving average is $32.18 and its two-hundred day moving average is $29.36. Celldex Therapeutics, Inc. has a 1 year low of $19.72 and a 1 year high of $39.16.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.80 million. Sell-side analysts predict that Celldex Therapeutics, Inc. will post -4.36 EPS for the current year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.